16th Nov 2016 09:28
LONDON (Alliance News) - Transdermal technology firm Futura Medical PLC on Wednesday said it has received positive results on studies for its MED2002 topical gel for erectile dysfunction.
The analysis carried out show "statistically significant" results for mild-to-moderate sufferers of erectile dysfunction but also suggested an increased strength dose may increase the gel's efficacy for moderate to severe dysfunction.
Futura said all existing oral treatment for erectile dysfunction offer at least two dose strengths and it will now adopt a similar strategy for MED2002.
"We believe the strategy of including two dosages of MED2002 in the remaining clinical development program to potentially treat as wide a range of ED sufferers as possible will maximise the potential of this breakthrough ED treatment," said Futura Chief Executive James Barder.
"This strategy is also mindful that, with MED2002's rapid speed of onset and favourable safety profile, two dose strengths may unlock the huge potential of an over-the-counter treatment in an indication where only one in three men are prepared to go to a doctor to seek treatment," he added.
Separately on Wednesday, Futura said it has appointed Ken James, currently a non-executive director, as an executive director and head of research and development.
James is the former head of consumer healthcare research and development at UK drug giant GlaxoSmithKline PLC.
Shares in Futura were up 2.6% to 58.20 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical